OBSN — Obseva SA Share News
0.000.00%
Last trade - 00:00- CH₣0.14m
- -CH₣2.20m
- $19.64m
ObsEva jumps on licensing deal with Organon for preterm labor drug
Swiss stocks - Factors to watch on May 26
Brief: Obseva SA Entered Into Open Market Sale Agreement With Svb Leerink LLC For Offering Of Up To $50.0 mln shares-SEC Filing
Brief: Obseva FY Net Loss At USD 83 Million
Brief: Obseva Provides Update On Yselty (Linzagolix) Clinical Development Program
ObsEva: Gains on additional positive data for menstrual drug from late-stage trials
Brief: Obseva Announces Additional Phase 3 Primrose 1 And 2 Study Results
ObsEva SA: Up on positive data from preterm labor treatment study
Swiss stocks - Factors to watch on November 9
Brief: Obseva Presented Two Late-Breaking Posters At ASRM 2020 Virtual Scientific Congress
Swiss stocks - Factors to watch on September 4
Brief: Obseva Announces $20 Mln Underwritten Offering And Concurrent Private Placement
Swiss stocks - Factors to watch on Aug 6
Brief: Obseva: Positive Results From Two Phase 3 Studies Of Yselty® (Linzagolix)
Brief: Obseva And Yuyuan Bioscience Technology Submit Pre-Ind Dossier For Nolasiban With Chinese NMPA
Brief: Obseva Posts Data Showing Efficacy Of Linzagolix In Potential New Indication For Treatment Of Adenomyosis
Brief: Obseva Announces Publication Of Abstracts From Phase 2B Edelweiss Trial Of Linzagolix In Endometriosis
Brief: Obseva To Increase Issued Share Capital By Creating Additional Treasury Shares
Brief: Obseva Appoints Fabien De Ladonchamps As CFO